- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Canadian Customs to levy tariffs on Nycomed
The Canadian Customs and Revenue Agency has decided to assess duties on Nycomed Amersham Imaging’s Omnipaque and Visipaque, according to Nycomed Amersham Canada. The move came after Mallinckrodt Medical alleged in June that Oakville, Ontario-based
The Canadian Customs and Revenue Agency has decided to assess duties on Nycomed Amersham Imagings Omnipaque and Visipaque, according to Nycomed Amersham Canada. The move came after Mallinckrodt Medical alleged in June that Oakville, Ontario-based Nycomed Amersham Canada was dumping its products on the Canadian market. On Nov. 15, the Canadian commissioner of customs and revenue extended the period of investigation for the charges, and on Dec. 31, made a preliminary determination that dumping had occurred. Nycomed Amersham Canada plans to contest the decision before the Canadian International Trade Tribunal, according to Jean-Pierre Huot, general manager. The tribunal will hold hearings on the case in March, Huot said.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.
FDA Clears AI-Powered Qualitative Perfusion Mapping for Cone-Beam CT
May 6th 2024Reportedly validated in more than 10 clinical trials, the AngioFlow perfusion imaging software enables timely identification of brain regions with cerebral blood flow reduction and those with significant hypoperfusion.
